# Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes

> **NCT06949982** · PHASE2 · RECRUITING · sponsor: **Sergey Orlov, MD** · enrollment: 60 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer (mCRC)
- Colorectal Neoplasms

## Interventions

- **COMBINATION_PRODUCT:** experimental group x-MAP
- **DRUG:** Regorafenib (BAY 73-4506)

## Key facts

- **NCT ID:** NCT06949982
- **Lead sponsor:** Sergey Orlov, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-17
- **Primary completion:** 2027-04
- **Final completion:** 2027-10
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06949982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06949982, "Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06949982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*